Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BMS-790052 in Combination With Peg-Interferon Alfa-2a and Ribavirin in Chronic Hepatitis C Genotype 4
NCT01448044Phase 3Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Dec 2011
- Primary completion
- Oct 2013
- Modality
- Small Molecules
- Countries
- 7
01
Overview
A Phase 3 trial of daclatasvir in hepatitis C (HCV), sponsored by Bristol Myers Squibb. Started Dec 2011; status: completed.
02
Drugs
daclatasvir
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT01448044.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01448044.